Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Kiora Pharmaceuticals (NASDAQ: KPRX) has announced its participation in the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT. President & CEO Brian M. Strem, Ph.D., will deliver a presentation updating investors on the company's pipeline developments.

The presentation will focus on two key clinical trials: the planned Phase 2 trials of KIO-104 for retinal inflammation treatment and KIO-301 for retinitis pigmentosa treatment. Investors can access the live presentation through Kiora's investor relations website (ir.kiorapharma.com), with replay available for 90 days on the events page.

Ecinitas, California--(Newsfile Corp. - April 4, 2025) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation at the 24th Annual Needham Virtual Healthcare Conference on Thursday, April 10th, 2025, at 2:15 pm EDT.

President & CEO, Brian M. Strem, Ph.D., will provide an update on the progress of the Company's pipeline and its planned Phase 2 clinical trials of KIO-104 for the treatment of retinal inflammation and of KIO-301 for the treatment of retinitis pigmentosa.

The presentation may be accessed live from the homepage of the investor relations section (ir.kiorapharma.com) of Kiora's website and will be available for replay for 90 days on the investor relations "events" page (ir.kiorapharma.com/news-events/events).

About Kiora Pharmaceuticals

Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).

In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn, as well as to visit our website and/or subscribe to email alerts.

Contacts:

Investors
investors@kiorapharma.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247286

FAQ

When is Kiora Pharmaceuticals (KPRX) presenting at the Needham Healthcare Conference 2025?

Kiora Pharmaceuticals will present on Thursday, April 10th, 2025, at 2:15 pm EDT during the 24th Annual Needham Virtual Healthcare Conference.

What clinical trials will KPRX discuss at the Needham Conference 2025?

KPRX will discuss planned Phase 2 clinical trials for KIO-104 (treating retinal inflammation) and KIO-301 (treating retinitis pigmentosa).

How can investors access KPRX's Needham Conference presentation?

Investors can access the live presentation through Kiora's investor relations website (ir.kiorapharma.com) and watch the replay for up to 90 days afterward.

What pipeline updates will KPRX present at the Needham Healthcare Conference?

KPRX will provide updates on two key products: KIO-104 for retinal inflammation and KIO-301 for retinitis pigmentosa, both entering Phase 2 clinical trials.